Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity initiates coverage on Eleco at 'buy'

(Sharecast News) - Analysts at Canaccord Genuity initiated coverage on Eleco with a 'buy' rating and 176.0p target price on Thursday as it wondered if the firm was poised to become "the next UK SaaS champion?". Canaccord Genuit said Eleco has "all the hallmarks of the next UK SaaS champion", in its view, noting that the group has "best-of-breed software" facing an industry that requires, and was being pushed towards, digitalisation.

"Digital transformation has historically been slow in the construction sector with industry reports estimating that circa 85% of constructors still use Excel, and that pen and paper (rather than digital tools) are used on circa 25% of job sites," said Canaccord, which noted that Eleco was exiting a more than three-year software-as-a-service transition with product-market fit across its suite of digital transformation solutions.

The Canadian bank pointed out that Eleco already counts more than 90% of the UK's top 100 construction contractors, 40 of the top 50 in Sweden, and 14 of the top 20 in Germany as customers, and said recent product development aimed at improving productivity and bridging the site/office divide could provide "a material upsell opportunity".

"Eleco's transformation has gone under the radar as the SaaS transition has resulted in group's revenue increasing 18% from FY21-24, but recurring revenue has increased 62% over the same period. Eleco reported a 19% FCF margin pre-SaaS transition and, in our view, has the potential to be at least a double-digit grower, implying strong 'Rule of 40' credentials. We view the current 2.6x FY25 EV/Sales multiple as too low for a potential 'Rule of 40' SaaS stock," concluded Canaccord.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.